Abstract The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma (EC) has introduced significant updates, including refined anatomic definitions and the incorporation of molecular subtypes such as POLE mutations, mismatch repair deficiency, and p53 abnormalities. Magnetic resonance imaging (MRI) remains the preferred modality for preoperative staging of EC due to its superior soft tissue contrast and functional imaging capabilities. This review discusses the technical considerations for MRI acquisition, with particular emphasis on the impact of the revised staging system on imaging interpretation. It highlights the role of MRI in evaluating eligibility for fertility-sparing treatments and in posttreatment surveillance. Radiologists must be familiar with these changes to ensure accurate staging and optimal patient management. Lastly, it elucidates the utility of imaging biomarkers such as apparent diffusion coefficient values, tumor size, and patterns of spread as potential surrogates for histologic and molecular classification. Integrating molecular profiling with MRI interpretation represents a critical advancement toward risk-adapted therapeutic strategies in endometrial cancer.
Sud et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: